Greenwich Pharmaceuticals Inc. (NASDAQ:GRPI) of FortWashington, Pa., said Monday that it submitted a new drugapplication (NDA) to FDA for Therafectin, a treatment for thesigns and symptoms of rheumatoid arthritis. Therafectin, asynthetic carbohydrate, may represent a new class of drugs totreat chronic autoimmune diseases such as rheumatoidarthritis.

(c) 1997 American Health Consultants. All rights reserved.

No Comments